Top Stories
The partners plan to explore the virtual models across multiple disease areas, starting with lung health, in a bid to rethink drug trials.
Nearly 2000 AI agents analysed genetic experiments involving millions of mouse brain cells in about 30 minutes, identifying potential disease mechanisms for scientists to investigate.
An initial pilot will test the round-the-clock support tool in patients with desmoid tumours and NF1-related plexiform neurofibromas.
Boston-based AI Proteins will create novel therapeutic candidates from scratch against undisclosed targets.
The AI firm will integrate Orchestra's AI agents with its Rosalind AI model and tools for life sciences research.
Conference News
EVX-01 induced an immune response in all patients in the trial with 89% of the vaccine neoantigens generating potent specific T-cell responses Three-year data from the EVX-01 phase 2 trial in patients...
New ESMO data from three trial-sized cohorts, and a 25-month analysis of GitLab co-founder Sid Sijbrandij’s osteosarcoma highlight the potential to extract meaningful insights from limited patient dat...
HighlightsThe Treat CKD tool, which draws on electric health records data, automates CKD identification, risk classification, and guideline-concordant treatment recommendations.The findings will be pr...
Study with Eigen Bio finds that longitudinal blood RNA can reveal biology underlying treatment response and resistance in BRAF V600E colorectal cancer.NEW YORK, NY, UNITED STATES, October 22, 2026 /EI...
Plasma-Informed Test Supports Longitudinal ctDNA Monitoring Without Prior Tumour-Tissue Profiling Medicover Genetics will launch OncoSentia MRD, a plasma-based test for longitudinal minimal residual d...
